Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson’s Disease

Table 1

Demographics and clinical symptomatology in late-stage PD (n = 107).

	Total cohort	Missing
Gender, n (%)		—
Male	62 (58%)
Female	45 (42%)
Age, median (q1–q3)	78 (73–84)	—
Age at onset (years), median (q1–q3)	63 (55–71)	—
PD duration (years), median (q1–q3)	15 (11–19)	—
LEDD, median (q1–q3)	798 (560–998)	—
Partner (yes), n (%)	65 (61%)	—
Disease severity (Hoehn and Yahr), n (%)		—
Stage IV	79 (74%)
Stage V	28 (26%)
Independence ADL (%) (Schwab and England), median (q1–q3)	40 (30–50)	—
Motor function (UPDRS III), median (q1–q3)	40 (29–53)	—
Nonmotor burden (NMSS, total score), median (q1–q3)	91 (55–128)	2
Cognitive impairment
MMSE total score, median (q1–q3)	22 (18–27)	4
Proportion ≤23, n (%)	60 (58%)
Proportion ≤18, n (%)	27 (26%)
Depressive symptoms
GDS-30, median (q1–q3)	11 (8–16)	7
Proportion ≥10, n (%)	63 (63%)

PD, Parkinson’s disease; q1–q3, first and third quartiles; LEDD, levodopa equivalent daily dose; HY, Hoehn and Yahr staging scale (score range I–V, higher = worse); S&E, Schwab and England ADL scale (score range 0–100, higher = better); UPDRS III, Unified PD Rating Scale, part III = motor examination (score range 0–108, higher = worse); MMSE, Mini-Mental State Examination (score range 0–30, higher = better); GDS-30, Geriatric Depression Scale (score range 0–30, higher = worse).